Inhaler approved for cystic fibrosis patients

(HealthDay)—The TOBI Podhaler (tobramycin inhalation powder) has been approved by the U.S. Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bacterium that can damage the lungs.

Cystic fibrosis, affecting about 30,000 people in the United States, causes production of thick, sticky mucus that builds up in the lungs. This can lead to chronic bacterial infections, the FDA said in a news release.

The TOBI Podhaler, used twice daily, was evaluated in clinical trials involving 95 adults and children six years and older with . The most common side effects included cough, coughing up blood, shortness of breath, fever, mouth and throat pain, changes in voice and headache.

The antibiotic inhaler is marketed by Novartis, based in East Hanover, N.J.

More information: Medline Plus has more about cystic fibrosis.

add to favorites email to friend print save as pdf

Related Stories

New proteins to clear the airways in cystic fibrosis and COPD

Jul 13, 2012

University of North Carolina scientists have uncovered a new strategy that may one day help people with cystic fibrosis and chronic obstructive pulmonary disorder better clear the thick and sticky mucus that clogs their lungs ...

Smoking cigarettes simulates cystic fibrosis

Oct 12, 2011

If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think. A new research report appearing online in the FASEB Journal shows that smoking cigarettes affects the lungs in a way th ...

Recommended for you

Supercomputers link proteins to drug side effects

12 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

19 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments